Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma.

This interaction was highly significant (HR, 2.29 [95% CI, 1.37 to 3.85]; P < .002), strengthening the evidence of PurIST subtypes as a predictive biomarker of treatment outcomes (Fig 3 D).

also in 132,142 other papers